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Abstract 
 
Background: Regional differences in presentation of uncomplicated urinary tract infection (UTI) and 
pathogen sensitivity to antibiotics have been used to justify variation in management, including 
broad spectrum antibiotic prescribing.  
 
Aim: To describe presentation and management of urinary tract infection in primary care settings, 
and explore the association with patient recovery, taking microbiological findings and case mix 
into account. 
 
Design and setting: Prospective observational study of women with symptoms of uncomplicated 
UTI presenting to primary care networks in England, Wales, the Netherlands, and Spain.  
 
Method: Clinicians recorded history, symptom severity, management, and requested mid-stream 
urine culture. Participants recorded symptom severity each day for 14 days in a diary. Time to 
recovery was compared between patient characteristics and between countries using two-level 
Cox proportional hazards models, with patients nested within practices. 
 
Results: 797 women attending primary care networks in England (246 (30·9%)), Wales (213 
(26·7%)), the Netherlands (133 (16·7%)) and Spain (205 (25·7%)) were included. 259 (35·7%, 95% CI 
32·3 to 39·2) were urine culture positive for UTI. Pathogens and antibiotic sensitivities were 
similar. Empirical antibiotics were prescribed for > 90% of women in England, Wales and Spain, but 
lower in the Netherlands. There were no meaningful differences at a country network level before 
and after controlling for severity, prior UTIs, and antibiotic prescribing.  
 
Conclusion: Variation in presentation and management of uncomplicated UTI at a country primary 
care network level is clinically unwarranted and highlights lack of consensus concerning optimal 
symptom control and antibiotic .prescribing. 
 
Funding 
The research leading to these results has received funding from the European Community's Seventh 
Framework Programme FP7/2007-2013 under grant agreement no. 282512. 
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Study registration 
REC reference: 12/WA/0111 
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How this fits in 
Regional ddifferences in presentation of uncomplicated urinary tract infection (UTI) and pathogen 
sensitivity to antibiotics have been used to justify variation in management, including broad 
spectrum antibiotic prescribing. However, regional differences in primary care presentation, 
management have not been prospectively described, and the association with patient recovery, 
taking microbiological findings into account, is unknown.  
 
Ours is the first prospective study to describe presentation and management of uncomplicated 
urinary tract infection in primary care settings in Europe, and explore the association with patient 
recovery, taking microbiological findings and case mix into account. We found little variation in 
patient presentation, or aetiology and sensitivity of urinary pathogens cultured in the urine of 
women with symptoms of uncomplicated UTI in four European primary care settings. However, the 
proportion of urine cultures meeting laboratory definitions of UTI, patients prescribed an antibiotic, 
antibiotic classes commonly prescribed, whether antibiotic choice was concordant with culture 
results, and subsequent consulting and prescribing did, however, differ markedly.  Despite these 
differences, patient reported recovery measures did not vary at the country network level, before 
and after controlling for severity, prior urine infections, and antibiotic prescribing. The most cost 
effective care pathway for uncomplicated UTI should now be determined and care standardised, as 
the current variation in care for UTI is not warranted on clinical grounds. 
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Introduction 
Variation in the presentation and management of symptoms of uncomplicated urinary tract 
infection (UTI) has been identified (1-3), but we do not know whether such variation is warranted by 
differences in symptom presentation, prevalence of microbiologically-confirmed UTI, characteristics 
of infecting pathogens between settings, and whether such factors are associated with patient 
recovery. Variation in antibiotic prescribing that is not warranted on clinical grounds could waste 
resources, put patients at unnecessary risk of delayed recovery and adverse events, and 
unnecessarily drive antimicrobial resistance, particularly where broad-spectrum antibiotics are used. 
Antibiotic resistance is a growing international problem that does not respect national borders.  
 
We previously investigated variation in antibiotic prescribing for acute cough/lower respiratory tract 
infection (LRTI) in Europe, and found a four-fold variation between primary care networks in 14 
countries that was not meaningfully associated with patient recovery, and huge variation in the 
choice of first line antibiotics.(4) This highlighted the need for standardising clinical care and 
promoting self-care.(5) While that analysis controlled for presentation and case mix, it was not able 
to take microbiological findings into account. This is important as clinicians may justify their 
antibiotic prescribing on the basis of assumed differences in patient characteristics as well as 
aetiology and presumed bacterial antibiotic susceptibility.(6, 7)    
 
Uncomplicated UTI is one of the most common bacterial infections managed in primary care.  Nearly 
40% of women report having had at least one UTI in their lifetime. More, more than 10% report at 
least one episode and about 3% report three or more episodes (recurrent UTI) in the past year.(8, 9) 
Most women in the UK consult a health professional when they have symptoms attributable to a 
UTI, and about three quarters of these have some form of urine test and are prescribed an antibiotic 
for their symptoms.(9) However, up to 70% of women with symptoms attributable to UTI are found 
not to have a UTI confirmed microbiologically when routine urine culture is performed, but this is 
dependent on the thresholds and criteria used by laboratories and study design and population.(10-
14) 
 
Antimicrobial stewardship interventions and clinical practice guidelines aimed at optimising standard 
routine care would therefore be enhanced by a better understanding of the variation in presentation 
and care (e.g. patient characteristics, dipstick results and requesting urine culture, proportion and 
appropriateness of antibiotic prescribing, non-antibiotic prescribing, planned follow-up 
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arrangement, subsequent antibiotic prescribing, and re-consultations), and the association with 
microbiological findings and recovery. We therefore aimed to describe variation in the presentation 
and the variation in management, and the association with outcomes for women presenting with 
symptoms of uncomplicated UTI to primary care research networks in four European settings.  
 
Methods 
Setting and participants 
This study was conducted in primary care general practices that were part of primary care networks 
in England, Wales, Spain and the Netherlands between November 2012 and February 2014. These 
primary care research networks were selected on the basis of having well-established primary care 
research capability and reflected the countries in which the investigators were based. Each primary 
care network aimed to recruit approximately 10 general practices based on their interest and 
capacity to deliver the study protocol. Each country network was set a target to recruit 200 eligible 
women. The primary care clinicians in the practices were asked to sequentially recruit adult women 
presenting with symptoms of uncomplicated UTI, record patient demographics, their usual care 
diagnostic procedures and treatment, and collect and send a urine sample for laboratory culture.   
 
Eligible participants were women aged 16 years or older, able to provide written informed consent, 
presenting to primary care with at least one of three key urinary tract symptoms (dysuria, urgency 
including nocturia, and frequency) and where the clinician suspected uncomplicated UTI (no known 
urological abnormalities, non-pregnant women). (15) Exclusions were: terminal illness, receiving 
treatment for life-threatening cancer, severe systemic symptoms, on long-term antibiotic treatment 
or have received antibiotics for urinary tract infection within the past four weeks, bladder surgery 
(including cystoscopy) within the past four weeks, significant immune compromise (e.g. long-term 
corticosteroid or chemotherapy, insulin dependent diabetes), functional or anatomical abnormalities 
of the genitourinary tract, history of pyelonephritis, and, pregnancy. Fever was not an exclusion.  
 
Clinical Examination 
On a case report form (CRF) clinicians were asked to record details of the participant’s presenting 
clinical symptoms including fever, pain in the side, blood in urine, smelly urine, burning or pain when 
passing urine, urgency, daytime frequency, night time frequency, tummy pain, restricted activities, 
and feeling generally unwell) using a scale of 0-6 for each feature (with 0 being ‘normal/not affected’ 
and 6 being ‘as bad as it could be’), temperature, their antibiotic management for the suspected UTI 
and any planned follow-up. This scale was similar to the one used in the patient diary, and represent 
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a slight modification of previously used instruments.(16) The severity of three symptoms (day-time 
frequency, night-time frequency, and urgency) were summed to create a GP-rated symptom severity 
score ranging from 0 to 18 (see online supplementary material for more detail). 
 
Antibiotic prescribing 
We assessed antibiotic prescribing at the index consultation (yes/no), and whether or not 
prescriptions were ‘concordant’ (a UTI on laboratory culture and prescribed antibiotics matching 
pathogen sensitivity, or, no UTI on culture with no antibiotic prescribed) or ‘not concordant’ (a UTI 
on laboratory culture and prescribed an antibiotic to which the pathogen was resistant, or, a UTI on 
culture and no antibiotic prescribed, or, no UTI on culture and an antibiotic prescribed). 
 
Urine dipstick and culture  
Participants were asked to provide a mid-stream urine sample at baseline, in addition to any urine 
samples the responsible clinician wished to obtain to guide usual care. Clinicians were asked to 
record whether they undertook urine dipstick testing and the results of dipstick tests performed, 
and whether the urine was cloudy or had an offensive smell. Urine samples were then referred by 
usual post to a microbiology laboratory (Public Health Wales Specialist Antimicrobial Chemotherapy 
Unit [PHW SACU] for England and Wales, Tarragona, Madrid and Bon Pastor respectively for Spain, 
and University Medical Center [UMC] Utrecht for the Netherlands) in a boric acid sample container 
for microbiological investigation. Isolated bacteria considered to be causing a UTI were frozen and 
subsequently sent to the PHW SACU laboratory in Cardiff where sensitivities to urinary tract 
antimicrobials were determined using agar dilution and the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) breakpoints. Urine samples were considered positive for UTI if pure 
or predominant (103 difference between the first and the second most abundant isolate on any 
subsequent pathogens) culture at ≥ 105 CFU/mL of any organisms.(17) We conducted a sensitivity 
analysis using a European definition that required a lower quantification threshold: ≥ 103 CFU/mL of 
any organism cultured.(18)  
 
Participant follow up 
Participants were asked to complete a paper daily diary each day for 14 days recording their 
symptoms (fever, pain in the side, blood in urine, smelly urine, burning or pain when passing urine, 
urgency, daytime frequency, night time frequency, tummy pain, restricted activities, and feeling 
generally unwell) on a scale of 0 (no problem) to 6 (as bad as it could be). Any follow up 
consultations for their UTI and medication use (including medication purchased over-the-counter) 
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was also recorded in the diary. Participants were contacted by telephone by the research team if 
diaries were not returned within an acceptable timeframe.  
 
All data collection forms were translated for use in Spain and the Netherlands and were back 
translated to check meaning and validity of translations. 
 
Patient-reported recovery 
Recovery was assessed in terms of time to full recovery (the first day that all 11 symptoms were 
scored zero (normal / not a problem)); time to resolution of moderately bad symptoms (the first day 
that all 11 symptoms were scored two (slight problem or less), and; time to resolution of daytime 
frequency, night-time frequency, and urgency (the first day that all three symptoms were scored 
zero). The latter recovery outcome was derived following a factor analysis of all 11 symptoms. See 
online supplementary material for more detail. 
 
Sample size estimation 
The sample size was based on achieving a 95% confidence interval of 45% to 55% around a 
prevalence of antibiotic prescribing estimate of 50%; 50% was chosen as this gave the most 
conservative estimate (higher or lower percentages will have produced narrower confidence 
intervals). This required 385 participants but was inflated to a total of 800 participants to account for 
an estimated practice-level intra-cluster correlation coefficient (ICC) of 0.057. This value is in line 
with previous work.(19) No additions were made to this sample size for potential dropout as data on 
prescribing antibiotics were collected at the initial baseline visit immediately after recruitment. 
 
Data Analysis 
Descriptive statistics by country and overall were calculated using means and standard deviations 
(SD) inflated for clustering, medians (interquartile ranges), and proportions as appropriate.  
The odds of having i.) a dipstick test performed; ii.) a microbiologically-confirmed UTI; iii.) being 
prescribed antibiotics; iv.) receiving an antibiotic prescription concordant with urine culture results; 
v.) having a urine sample that would have normally been sent for culture by a GP; vi.) having a 
planned follow-up arrangement; vii.) being prescribed subsequent antibiotics; and viii.) re-consulting 
in the two-weeks following the index consultation were compared between various patient 
characteristics and between countries using two-level logistic regression models, with patients 
nested within practices. The practice-level ICC was estimated using the standard π2/3 estimator.(20)  
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Time to recovery (full recovery, resolution of moderately bad symptoms, and resolution of daytime 
frequency, night-time frequency, and urgency) was compared between various participant 
characteristics and between countries using two-level Cox proportional hazards models, with 
participants nested within practices. 
 
Results are presented as odds ratios or hazard ratios, with 95% confidence intervals and p-values. 
Candidate variables related to case-mix comprised: age of participant at baseline; clinician-rated 
symptom severity score; number of days off work (0/1 or more); previous number of days with 
symptoms (0 to 7/8 to 14/15 to 21/22 or more); level of leukocytes found in urine on dipstick testing 
(negative/+/++/+++); presence of nitrites, protein, blood and pH level of urine (5 to 7/7·5 to 8·5) on 
dipstick testing; cloudy urine; offensive smelling urine; temperature of participant at baseline; 
diagnosed with a urine infection in the past; number of treated urine infections in the past year 
(0/1/2/3 or more). Candidate variables related to patient management comprised: performed a 
dipstick test; would have collected urine sample under normal circumstances; prescribed an 
antibiotic; organised follow-up. All candidate variables that were associated with the response 
variable at the 10% significance level (p-value <0·1) in a univariable model were entered into a 
multivariable model. The findings from the univariable analyses can be viewed in the online 
supplementary material. We compared each country to the overall average in our regression models 
using a sum-to-zero contrast. However, we also compared each country to England (the country 
from whom we recruited the most number of participants (21) to ensure our findings were not 
strongly influenced by our choice of contrast.(21) 
 
Data management was performed using IBM SPSS Statistics 20. (22) All analyses were performed 
using R (version 3.0.1) (23) and the lme4 package.(24)  
 
Ethical Approval 
A Research Ethics Committee recognised by the United Kingdom Ethics Committee Authority 
(UKECA) and relevant European Committees in the Netherlands and Spain approved the study.  
 
Role of the funding source 
The funders had no role in determining the study design, data collection, analysis, writing the report 
and in the decision to submit the paper for publication. The corresponding author had full access to 
all the data in the study and had final responsibility for the decision to submit for publication.  
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Results 
A total of 797 women were included, with a smaller proportion recruited in the Netherlands 
(England n = 246, Wales n = 213, Spain n = 205, and the Netherlands n = 133). Baseline data was 
returned for 793 participants. Urine samples that were analysed for the primary UTI identification 
were provided by 726 participants (91·1%). For the missing samples, urines were either not provided 
(n= 39), leaked on transit (n= 24) to the laboratory or were unable to be processed by the laboratory 
(n= 5). The two-week follow-up diary was returned by 567 participants (71·1%) (Figure 1). Those who 
did not return their diaries were younger on average (median age 34 years, interquartile range (IQR) 
23 to 48 years vs. median 50 years, IQR 35 to 64 years), but had similar GP rated symptom severity 
scores at enrolment. 
 
Presentation 
Symptom severity at baseline, as rated by recruiting GPs, were lowest for participants in Spain (mean 
8·1, SD 3·65), followed by the Netherlands (mean 9·8, SD 4·19), England (mean 10·1, SD 4·00) and 
then Wales (mean 10·5, SD 4·57).  Participants in the Netherlands were symptomatic for longer 
before consulting (median number of days 5, IQR 3- to 10 days) vs. overall median of 3 days, IQR 2 to 
7 days). Median age ranged from 39 years (IQR 27 to 54 years) in Wales to 50 years (IQR 31 to 63 
years) in England. The proportion in paid employment was similar in Wales, England and the 
Netherlands but slightly lower in Spain. The proportion that had taken one or more days off work 
was highest in England and lowest in the Netherlands. Before consulting, 184 participants (32·5%, 
ranging from 1·3% (2/155) in Spain to 46·6% (61/131) in Wales) reported that they tried managing 
their urine infection with cranberry juice. Mean body temperature at baseline was normal in all 
networks (Table 1).  
 
Dipstick testing 
A total of 669/791 (84·6%) participants had a dipstick test performed at baseline, with the highest 
number of tests performed in the Netherlands (127/133, 95·5%) and the lowest in Spain (141/205, 
68·8%).  
 
Microbiological confirmation of a UTI 
Overall, 259/726 (35·7%, 95% CI 32·3 to 39·2) participants were identified with a UTI according to 
our primary microbiological definition, with similar proportions in England (24·3%, 95% CI 19·1 to 
30·4) and Wales (24·1%, 95% CI 18·7 to 30·5) but higher in Spain (42·3%, 95% CI 35·4 to 49·6) and in 
the Netherlands (63·8%, 95% CI 55·1 to 71· 6). Enterobacteriaceae (most commonly Escherichia coli) 
were implicated in 88·8% (230/259) and Coagulase negative staphylococci in 5·8% (15/259) of UTIs 
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(Table 2). Resistance to at least one of the tested antibiotics was recorded in 52·7% (110/209) of 
isolated strains. Trimethoprim resistance was similar between countries (16·7% (8/48) in England to 
22·7% (10/44) in Wales) but nitrofurantoin resistance was higher in England and the Netherlands. 
However, numbers are small (Table 3).  
 
Slightly more participants had a microbiologically confirmed UTI according to the European 
definition for a UTI, which requires a lower quantification threshold of 103 CFU/mL (285 participants, 
39·3%). The prevalence of UTI in the Netherlands (65·4%, 83/127) remained at the highest compared 
to other countries (England: 22·5%, 49/218; Wales: 26·6%, 53/199; Spain: 54·9%, 100/182) using this 
definition. 
 
Antibiotic prescribing 
A total of 232/244 participants in England (95·1%), 196/211 in Wales (92·9%), 195/205 in Spain 
(95·1%) and 79/133 in the Netherlands (59·4%) were prescribed empirical antibiotics (Table 4). After 
adjusting for participant characteristics, the odds of being prescribed an antibiotic were 150% higher 
for participants in England (OR: 2·50, 95% CI 1·11 to 5·62, p=0·027) compared to the overall average. 
The odds of being prescribed an antibiotic in the Netherlands were 82% lower (OR: 0·18, 95% CI 0·08 
to 0·39, p<0·001) compared to the overall average. Changing the comparison from the overall 
average to comparing countries to England, we found that participants in Wales and The 
Netherlands had lower odds of receiving an antibiotic prescription (multivariable odds ratio for 
Wales: 0·28, 95% CI: 0·08 to 0·97; The Netherlands: 0·07, 95% CI: 0·02 to 0·27). The odds of being 
prescribed an antibiotic were also higher for those participants with a positive dipstick test for blood 
in urine (OR: 2·95, 95% CI 1·42 to 6·14, p=0·004) or having a higher clinician-rated symptom severity 
score (for one-unit increase OR: 1·20, 95% CI 1·10 to 1·31, p<0·001). Trimethoprim was the most 
commonly prescribed antibiotic in Wales (76·5%, 150/196), fosfomycin in Spain (75·9%, 148/195), 
nitrofurantoin in the Netherlands (79·7%, 63/79), and trimethoprim and nitrofurantoin in England 
(46·1%, 107/232 and 48·7%, 113/232 respectively). Spain had the highest proportion of co-amoxiclav 
(9·7%, 19/195) and ciprofloxacin (9·2%, 18/195) prescribing. Ten participants (1·4%) received a 
prescription for cephalosporins (Table 4). Overall, 13/702 (1·9%) participants were given a delayed 
antibiotic prescription. 
 
A total of 225/675 (33·3%) participants were prescribed an antibiotic that was concordant with the 
culture result (antibiotic class matched to a microbiological definition for UTI on culture and to 
pathogen sensitivity as well as those who did not have a microbiological UTI and were not prescribed 
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an antibiotic). The Netherlands had the highest proportion of concordant prescribing and Wales had 
the lowest (66·7%, 82/123 compared to 23·8%, 46/193). In total 450/675 (66·7%) participants were 
prescribed antibiotic non-concordantly. Overall, most non-concordant antibiotic prescribing related 
to women with a culture negative for UTI being prescribed an antibiotic (400 women, 59·3%), and 
few prescriptions were non-concordant because of resistance to the prescribed antibiotic (28/675, 
4·8%) (Table 3). The proportion of participants prescribed a concordant antibiotic was almost 
identical (32·5%, 203/625) when the European laboratory criteria for UTI were used.  
 
Non-antibiotic prescribed medication   
Spain had the highest proportion of prescribed paracetamol (20·5%, 42/205) or ibuprofen (5·9%, 
12/205), whilst England had the highest proportion of clinicians who advised their patients to take 
paracetamol (28·5%, 70/246) or ibuprofen (10·6%, 26/246). Prescriptions for paracetamol or 
ibuprofen, or advice to self-medicate with these was negligible in the other research networks. 
 
Planned follow-up with a GP or nurse 
Overall, 225/779 (28·9%) participants had follow-up contact arranged with a GP or nurse. This varied 
widely between countries, from 12% (30/242) of participants in England to 55% (112/204) of those 
in Spain.  After adjusting for participant characteristics, having a follow-up contact arranged was 
associated with the age of the participant (OR for ten-year increase: 1·16, 95% CI 1·01 to 1·32, 
p=0·029), presence of Leukocytes (+++ result compared to a negative result: 0·43, 95% CI 0·21 to 
0·88, p=0·021), positive dipstick test for nitrites (OR: 0·55, 95% CI 0·32 to 0·96, p=0·035), having 
cloudy urine (OR: 1·69, 95% CI 1·00 to 2·86, p=0·049) and temperature of participant (OR for one 
degree Celsius increase: 1·83, 95% CI 1·10 to 3·04, p=0·019). 
 
Participant recovery 
The median time to full recovery was 10 days (IQR: 6 to 14 days). However, it was 9 days for those 
who had a microbiologically confirmed UTI (IQR: 6 to 14 days), and 10 days for those who did not 
(IQR: 6 to 14 days). Antibiotic prescription at the index consultation was associated with time to full 
recovery (adjusted HR = 1·69, 95% CI 1·05 to 2·72, p=0·006). Those who were prescribed an 
antibiotic recovered faster than those who were not (median 9 days (IQR 5 to 14 days) vs. 13 (IQR 7 
to 14 days)). While the median time to recovery in those who had a microbiologically confirmed UTI 
and were prescribed antibiotics was the shortest, and those who had neither the longest, there was 
no evidence of any differential association between antibiotic prescribing and a microbiologically 
confirmed UTI (Section 2.1 of the online supplementary material). There was also no evidence of any 
differences in recovery at a country level. Similarly, there was no evidence of any differences by 
country in the time to resolution of moderately bad symptoms (median: 4 days, IQR: 2 to 6 days)  or 
daytime frequency/night-time frequency/urgency (median: 8 days, IQR: 4 to 14 days) (See Tables in 
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sections 3 and 4 of the online supplementary material). Findings were similar in unadjusted and 
adjusted models (see Tables in section 2 of the online supplementary material). 
 
Subsequent antibiotic prescribing 
In the two weeks following inclusion, 55/531 (10·4%) participants were prescribed at least one 
subsequent antibiotic for their UTI symptoms, with 19/133 participants in Wales (16·8%), 24/165 in 
England (14·5%), 11/104 in Netherlands (10·6%), and 1/147 in Spain (0·7%).  
 
Re-consultation 
During the follow up period, 130/547 (23·8%) participants reported that they had consulted with 
their GP or out of hours’ provider for their UTI symptoms, with 41/121 participants in Wales, 28/102 
in Netherlands (27·5%), 47/172 in England (27·3%), and 14/152 in Spain (9·2%). 
 
Discussion 
This observational study of the presentation, management and outcomes of uncomplicated UTI in 
primary care in four European countries involving nearly 800 well described participants found 
remarkably little differences in GP rated symptoms severity at presentation, pathogens and 
sensitivity, but considerable differences in UTI positivity on culture, antibiotic prescribing, 
subsequent antibiotic prescriptions and re-consultations at the country primary care network level. 
Antibiotic prescribing was favourably associated with recovery. However, there was no notable 
difference in participant recovery at the country -level, after controlling for case-mix and initial 
antibiotic prescribing. Delayed antibiotic prescribing was rare, as were non-antibiotic prescriptions. 
These findings indicate considerable unwarranted clinical variation in care, particularly in the use of 
broad spectrum antibiotics, and thus highlight opportunity for determining the most cost effective 
pathway of care for uncomplicated UTI to minimise unnecessary exposure to antibiotics. 
 
Comparison with existing studies 
Our systematic search in January 2014 (10, 11, 13, 14, 25-32) and update in November in 2016(2, 33, 
34) found that ours is the first prospective study that compared routine management of urinary tract 
infection in primary care between country settings, taking case mix and microbiological findings into 
account. 
Daytime frequency and urgency were both the most prevalent and severely graded (as ‘bad’) 
symptoms across all networks. Frequency and dysuria were the most prevalent symptoms reported 
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in previous European studies, although urgency was reported by fewer studies and had a lower 
prevalence.(11, 26, 27, 32, 34) Women in the Netherlands waited longer before consulting: this may 
explain to some extent the higher proportion of those with a microbiological confirmed UTI.  
Urinalysis dipsticks were the most commonly used tests across all four networks, and was similar to 
studies in Spain, Sweden and Germany and where use of dipstick urinalysis ranged from 84% to 
93%.(25, 29, 32)  
We identified UTI on culture in 35·7% of cases overall, with similar proportions in England and Wales 
(24·3% and 24·1% respectively), but much higher in Spain (42·3%) and the Netherlands (63·8%). 
Vellinga and colleagues found that 70% of urines from patients with suspected UTI had no evidence 
of UTI on culture in a study in Ireland.(14) Hummers-Pradier found 65·6% of patients in Germany had 
a positive result (using a definition of 103 CFU/mL and no more than two pathogens),(29) and 
Etienne(33) found 78% had a positive urine culture in a French study; however both of these studies 
used a lower threshold for positivity compared to our primary definition. Three UK studies reported 
positivity of samples between 25% and 38%(10, 13, 27), while Little and colleagues’ observational 
study, also in the UK, found that 50% of women with symptoms attributed to a UTI met similar 
microbiological criteria for a UTI that was used in our study (16) and they also found that women 
treated with antibiotics recovered faster.(11)  
As with our study, Etienne and colleagues found that Escherichia coli predominated with generally 
high rates of sensitivity to commonly used antibiotics; 13% of isolates resistant to trimethoprim-
sulfamethoxazole compared to our overall finding for trimethoprim resistance of 18·7%.(33)   
 
In our study overall, antibiotics were prescribed for 88·5% (59·4% in the Netherlands and over 92% in 
the other settings). Antibiotic prescribing ranged from 56% to 98·6% in previous European studies.(14, 
26, 29) Two English studies(11, 27) found prescribing rates similar to those we report for our network 
in England, and a Spanish study found a similar proportion to the prescribing rate in our Spanish 
network.(32) A Welsh study found a much lower prescribing rate than ours, but that study relied on 
patient recall of antibiotic prescription rather than GPs recording this at the time of consultation.(10)  
Trimethoprim (in Wales), nitrofurantoin (in Wales, England and the Netherlands) and fosfomycin (in 
Spain) were prescribed most commonly in our study.  The highest proportion of quinolone 
prescription was in the Spanish network, where high levels of quinolone prescribing for 
uncomplicated UTI has previously been identified.(30, 33) Studies from across Europe also 
demonstrate the wide variation between counties in choice of antibiotics prescribed for 
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uncomplicated UTI.(2, 25, 26, 28, 30, 31, 33, 34) 
 
We found that guideline concordant antibiotic prescribing ranged from 23·8% in Wales to 66·7% in 
the Netherlands. Philips and colleagues compared adherence to guidelines regarding the type of 
antibiotics prescribed for the primary care out of hours’ management of UTI in four European 
countries, and found that adherence to antibiotic prescribing guidelines ranged from 25% to 100%.(1) 
Other studies have similarly confirmed poor adherence to guidelines for managing uncomplicated UTI 
in primary care.(2, 25, 26, 30, 32, 35)  
 
Strengths and weaknesses 
We deliberately did not try to standardise investigations and management across the centres 
because our goal was to describe variation and explore whether any variation we identified was 
associated with recovery and microbiological findings and thus clinically warranted.  This prospective 
study recruited participants using the same eligibility criteria, outcome measures and data collection 
tools in four contrasting European settings, and was adequately powered to determine variation at a 
primary care network level. Susceptibility testing was standardised in a central microbiology 
research laboratory.  However, diary return rates were lower in Wales and women recruited in 
Wales tended to be younger than in the other networks. Clinicians may have altered their behaviour 
because of research conditions, despite clear communication that our purpose was to describe 
routine care. Their assessment of the patents’ symptoms at study inclusion may have been 
influenced by personal, interpersonal, and cultural factors. In addition, while our study largely met 
our pre-specified power requirements, relatively few patients from each network were included, and 
fewer participants were recruited in the Netherlands.  
 
We did not include primary care research networks in an Eastern or Northern European country. 
Participating networks were local organising groups that recruited general practices into the study. 
Networks were selected partly because of their research experience and their ability to implement 
the study protocol to a high standard. We do not suggest that each of the four networks necessarily 
reflect consulting behaviour and care of the whole country.  Study participants may have been 
selectively rather than sequentially invited to participate, and we have no reliable logs of patients 
who were eligible but not invited to participate. Studies in both hospitals and primacy care that rely 
on opportunistic recruitment of acutely unwell patients during times of busy service delivery may be 
prone to selection bias that is hard to fully assess. Not all clinicians in the practices were 
participating in the study, and not all of those who did participate worked full time or 
recruited each time they were at work.   
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Participants for whom we have outcome data were older but with similar symptom severity scores 
at inclusion compared to those lost to follow up. While local laboratories followed their standard 
operating procedures for urinalysis and storage of microorganisms, sample transport times and 
arrangements may have differed.  Usual primary care management of uncomplicated UTI in the 
Netherlands, where we identified the biggest differences in UTI positivity and antibiotic prescribing, 
differs in important ways from the other countries. For example, it is common for symptomatic 
women to first drop off a urine sample at the practice, and if positive for nitrite on dipstick, it is then 
tested with a dipslide culture, before any antibiotic prescribing decision is made and urine sent for 
laboratory culture. In addition, the higher proportion of women who were positive for a UTI on 
culture may be related to waiting longer before consulting.  
Implications 
We have demonstrated little variation in presentation, pathogens and sensitivity of pathogens 
causing UTI in four European settings. However, in contrast, the proportion meeting laboratory 
definitions of UTI, the proportion prescribed an antibiotic, the antibiotics commonly prescribed, 
subsequent antibiotics prescribed, and consulting behaviour did differ markedly.  Despite this, a 
variety of participant-reported recovery measures showed no variation at the country level. 
Antibiotics were associated with improved outcomes overall. While more of the UTI treatment in the 
Netherlands was “concordant" according to our study definition, it was also at a cost of 
undertreating microbiologically confirmed UTI at a higher rate than other countries (16% versus <1% 
for other countries). 
Further research needs to better define the relationship between microbiological findings (using 
optimal diagnostic testing), patient symptoms at presentation, prognosis, and response to 
antimicrobials. Given the low rates of microbiologically-confirmed UTI on culture, especially in the 
UK, and response of some women with uncomplicated UTI to non-antibiotic treatment such as 
ibuprofen(36), it is likely that symptoms of uncomplicated UTI represent a syndrome that is cause by 
a range of aetiology that includes infection that may or may not be routinely cultured,(37) but also 
inflammation at various sites in the urinary tract due to non-infectious causes. The most cost 
effective care pathway for managing symptoms of uncomplicated UTI should now be determined 
and care standardised to maximise symptom resolution, resource use, and better targeted antibiotic 
prescribing, as current variation in care is not warranted on clinical grounds. 
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Table 1: Participant characteristics at study inclusion  
Demographic Wales England Spain Netherlands Overall 
 n  n  n  n  N  
Age at baseline (Median, IQR) 
211 
39 years 
(27, 54) 245 
50 years  
(31, 63) 205 
45 years  
(30, 61) 133 
45 years  
(34, 62) 793 
45 
(30, 61) 
GP symptom severity 
score (Mean, SD) 
Urgency 204 
3·6 
(1·9) 239 
3·7 
(1·6) 205 
2·9 
(1·6) 133 
3·2 
(1·8) 781 
3·4 
(1·7) 
Daytime 
frequency 203 
3·8 
(1·7) 239 
3·6 
(1·4) 205 
3·1 
(1·48) 133 
3·4 
(1·58) 780 
3·5 
(2·45) 
Night time 
frequency 202 
3·0 
(2·0) 239 
2·9 
(1·8) 205 
2·1 
(1·6) 132 
2·5 
(1·9) 778 
2·7 
(1·9) 
Summary 
score of 
above 
three-items 202 
10·5 
(4·6) 239 
10·1 
(4·0) 205 
8·1 
(3·8) 132 
9·1  
(4·2) 778 
9·5  
(4·2) 
Paid employment 
Yes (%) 132 62·6 147 60·2 88 42·9 84 63·2 451 56·9 
No (%) 79 37·4 97 39·8 117 57·1 49 36·8 342 43·1 
Of those who work; has 
they been off work 
because of this illness 
0 (%) 114 90·5 107 78·7 72 84·7 77 96·2 370 86·7 
1 or more 
days (%) 12 9·5 29 21·3 13 15·3 3 3·8 57 13·3 
Number of days with symptoms before 
consulting 
(Median, IQR) 210 3 (2, 7) 240 4 (2, 6) 204 2·5 (1, 5) 131 5 (3, 10) 785 3 (2, 7) 
Temperature at baseline  
(degree Celsius) (Mean, SD) 204 
36·6  
(0·5) 239 
36·7 
(0·5) 205 
36·2 
(0·4) 122 
36·7 
(0·5) 770 
36·5 
(0·5) 
Managing their UTI with 
cranberry juice* 
Yes (%) 61 46·6 81 45·8 2 1·3 40 38·1 184 32·5 
No (%) 70 53·4 96 54·2 153 98·7 65 61·9 383 67·5 
*Based on participants who had returned diaries 
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Table 2: Prevalence of UTI and urinary pathogens identification 
 
Wales England Spain Netherlands Overall 
n % n % n % n % N % 
No UTI 
confirmed 
Mixed growth (2 
or more 
organisms) 
103 51.8 118 54.1 9 4.9 37 29.1 267 36.8 
Single organism 
grow at <105 
34 17.1 37 17.0 26 14.3 2 1.6 99 13.6 
No growth 14 7.0 10 4.6 34 18.7 7 5.5 65 9.0 
Unclear organism 
names (mixed 
growth) 
0 0.0 0 0.0 36 19.8 0 0.0 36 5.0 
TOTAL 151 75·9 165 75·7 105 57·7 46 36·2 467 64·3 
UTI-confirmed 
Pure culture at 
105 or above 
34 17.1 38 17.4 77 42.3 81 63.8 230 31.7 
Predominant 
culture at 105 or 
above  
14 7.0 15 6.9 0 0.0 0 0.0 29 4.0 
TOTAL 48 24·1 53 24·3 77 42·3 81 63·8 259 35·7 
Urinary 
pathogen 
identification* 
Enterobacteriace
ae 
44 91·7 48 90·6 66 85·7 72 88·9 230 88·8 
Coagulase 
negative 
staphylococci (S· 
saprophyticus) 
2 4·2 1 1·9 9 11·7 3 3·7 15 5·8 
Other pathogens 2 4·2 4 7·6 2 2·6 6 7·3 14 5·6 
Total 48 100·0 53 100·0 77 100·0 81 100·0 259 100·0 
*Based on those who have a microbiologically-confirmed UTI 
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Table 3: Resistance profiles of identified urinary pathogens* 
 Wales  
(n=44) 
England 
(n=48) 
Spain 
(n=44) 
The Netherlands 
(n=73) 
Total 
(n=209) 
 n % n % n % n % n % 
Amoxicillin 15 34·1 25 52·1 27 61·4 18 24·7 85 40·7 
Trimethoprim  10 22·7 8 16·7 8 18·2 13 17·8 39 18·7 
Co-amoxiclav 0 0·0 4 8·3 12 27·3 0 0·0 16 7·7 
Nitrofurantoin 0 0·0 4 8·3 1 2·3 6 8·2 11 5·3 
Fosfomycin 3 6·8 2 4·2 3 6·8 3 4·1 11 5·3 
Ciprofloxacin 2 4·5 1 2·1 2 4·5 2 2·7 7 3·3 
Gentamicin 1 2·3 2 4·2 1 2·3 1 1·4 5 2·4 
Cefalexin 0 0·0 2 4·2 2 4·5 1 1·4 5 2·4 
Meticillin 0 0·0 2 4·2 3 6·8 0 0·0 5 2·4 
Cefotaxime 0 0·0 2 4·2 0 0·0 2 2·7 4 1·9 
Ceftazidime 0 0·0 1 2·1 1 2·3 2 2·7 4 1·9 
Ertapenem 0 0·0 1 2·1 2 4·5 0 0·0 3 1·4 
Temocillin 0 0·0 0 0·0 0 0·0 0 0·0 0 0·0 
 
Sensitive to all tested antibiotics 24 54·5 16 33·3 13 29·5 46 63·0 99 47·4 
Resistant to single antibiotic 12 27·3 18 37·5 13 29·5 14 19·2 57 27·3 
Resistant to more than one 
antibiotic 8 18·2 14 29·2 18 40·9 13 17·8 53 25·4 
*Based on those who have a microbiologically-confirmed UTI 
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Table 4: Antibiotic prescriptions at the initial consultation 
 
Wales England Spain Netherlands Overall 
n % n % n % n % N % 
No Prescribed antibiotics 15 7·1 12 4·9 10 4·9 54 40·6 91 11·5 
Prescribed antibiotics 196 92·9 232 95·1 195 95·1 79 59·4 702 88·5 
Prescription of 
antibiotic 
Fosfomycin  0 0·0 0 0·0 148 75·9 5 6·3 153 21·8 
Trimethoprim 150 76·5 107 46·1 0 0·0 9 11·4 266 37·9 
Nitrofurantoin  34 17·3 113 48·7 6 3·1 63 79·7 216 30·8 
Co-amoxiclav 2 1·0 1 0·4 19 9·7 1 1·3 23 3·3 
Cephalosporins 3 1·5 5 2·2 2 1·0 0 0·0 10 1·4 
Ciprofloxacin 2 1·0 0 0·0 18 9·2 1 1·3 21 3·0 
Other antibiotic* 5 2·6 6 2·6 2 1·0 0 0·0 13 1·9 
OR for receiving an antibiotic prescription (95% 
CI), p-value†‡ 
0·70  
(0·34, 1·46), 0·346 
2·50 
(1·11, 5·62), 0·027 
3·22 
(1·32, 7·86), 0·010 
0·18  
(0·08, 0·39), <0·001 
1·00 
            
Concordant 
antibiotic 
prescriptions 
UTI & antibiotic & sensitive 33 17·1 40 19·0 38 25·7 51 41·5 162 24·0 
No UTI & no antibiotic 13 6·7 12 5·7 7 4·7 31 25·2 63 9·3 
Total 46 23·8 52 24·6 45 30·4 82 66·7 225 33·3 
non-concordant 
antibiotic 
prescriptions  
 
UTI & antibiotic & resistance 10 5·2 8 3·8 4 2·7 6 4·9 28 4·1 
UTI & no antibiotic 1 0·5 0 0·0 1 0·7 20 16·3 22 3·3 
No UTI & antibiotic 136 70·5 151 71·6 98 66·2 15 12·2 400 59·3 
Total 147 76·2 159 75·4 103 69·6 41 33·3 450 66·7 
Overall 193 100·0 211 100·0 148 100·0 123 100·0 675 100·0 
OR for receiving an concordant antibiotic 
prescription (95% CI), p-value†§ 
0·57 
(0·43, 0·77), <0·001 
0·60 
(0·45, 0·79), <0·001 
0·80 
(0·59, 1·08), 0·144 
3·66 
(2·67, 5·02), <0·001 
1·00 
*Other antibiotic includes: Amoxicillin, Metronidazole, Pipemidic Acid and Doxycycline· †Two-level model (with Centre as the 2nd level and Participants as 
the 1st level)· ‡Compared to the overall average· Adjustment made for participant characteristics including; age, clinician-rated symptom severity score, 
previous number of days with symptoms, positive protein test, and positive blood test· Model based on 455 participants (57·1%) nested within 47 practices, 
Practice-level ICC=0·140· §Adjusted for country.
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18. Grabe M, Bjerklund-Johansen TE, Botto H, Çek M, Naber KG, Pickard RS, et al. Guidelines on 
Urological Infections: European Association of Urology; 2013 [Available from: http://uroweb.org/wp-
content/uploads/18_Urological-infections_LR.pdf. 
19. Flottorp S, Oxman AD, Havelsrud K, Treweek S, Herrin J. Cluster randomised controlled trial 
of tailored interventions to improve the management of urinary tract infections in women and sore 
throat. BMJ. 2002;325(7360):367. 
20. Snijders TAB, Bosker RJ. Multilevel Analysis: An Introduction to Basic and Advanced 
Multilevel Modeling. London: Sage Publishers; 2012. 
21. Hardy M. Regression with Dummy Variables. Newbury Park, CA: Sage; 1993. 
22. IBM C. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp.; 2011. 
23. Team. RC. A language and environment for statistical computing. Vienna, Austria: R 
Foundation for Statistical Computing; 2012. 
24. Bates D, Maechler M, Bolker B. Linear mixed-effects models using S4 classes. R package 
version 0.999999-0 ed2012. 
25. Andre M, Molstad S, Lundborg CS, Odenholt I, Swedish Study Group on Antibiotic U. 
Management of urinary tract infections in primary care: a repeated 1-week diagnosis-prescribing 
study in five counties in Sweden in 2000 and 2002. Scand J Infect Dis. 2004;36(2):134-8. 
26. Canbaz S, Peksen Y, Tevfik Sunter A, Leblebicioglu H, Sunbul M. Antibiotic prescribing and 
urinary tract infection. Int J Antimicrob Agents. 2002;20(6):407-11. 
27. Fahey T, Webb E, Montgomery AA, Heyderman RS. Clinical management of urinary tract 
infection in women: a prospective cohort study. Fam Pract. 2003;20(1):1-6. 
28. Galatti L, Sessa A, Mazzaglia G, Pecchioli S, Rossi A, Cricelli C, et al. Antibiotic prescribing for 
acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother. 
2006;57(3):551-6. 
29. Hummers-Pradier E, Ohse AM, Koch M, Heizmann WR, Kochen MM. Management of urinary 
tract infections in female general practice patients. Fam Pract. 2005;22(1):71-7. 
30. Martinez MA, Inglada L, Ochoa C, Villagrasa JR, Spanish Study Group On Antibiotic T. 
Assessment of antibiotic prescription in acute urinary tract infections in adults. J Infect. 
2007;54(3):235-44. 
31. Skerk V, Skerk V, Jaksic J, Lakos AK, Matrapazovski M, Malekovic G, et al. Research of urinary 
tract infections in family medicine physicians' offices--empiric antimicrobial therapy of urinary tract 
infections--Croatian experience. Coll Antropol. 2009;33(2):625-31. 
32. Llor C, Rabanaque G, Lopez A, Cots JM. The adherence of GPs to guidelines for the diagnosis 
and treatment of lower urinary tract infections in women is poor. Fam Pract. 2011;28(3):294-9. 
33. Etienne M, Lefebvre E, Frebourg N, Hamel H, Pestel-Caron M, Caron F, et al. Antibiotic 
treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons 
from a primary care series. BMC Infect Dis. 2014;14:137. 
34. Willems CS, van den Broek D'Obrenan J, Numans ME, Verheij TJ, van der Velden AW. Cystitis: 
antibiotic prescribing, consultation, attitudes and opinions. Fam Pract. 2014;31(2):149-55. 
35. Vellinga A, Galvin S, Duane S, Callan A, Bennett K, Cormican M, et al. Intervention to improve 
the quality of antimicrobial prescribing for urinary tract infection: a cluster randomized trial. CMAJ. 
2016;188(2):108-15. 
36. Gagyor I, Haasenritter J, Bleidorn J, McIsaac W, Schmiemann G, Hummers-Pradier E, et al. 
Predicting antibiotic prescription after symptomatic treatment for urinary tract infection: 
development of a model using data from an RCT in general practice. Br J Gen Pract. 
2016;66(645):e234-40. 
37. McLellan LK, Hunstad DA. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol 
Med. 2016. 
  
 Page 25 of 39 
ONLINE SUPPLEMENTARY MATERIAL: 
1. Description of factor analysis to create GP-rated symptom severity score and ‘time to resolution of day-
time frequency, night-time frequency, and urgency’ variable 
GP-rated symptom severity score 
All 11 GP-rated symptoms were subject to a factor analysis to determine if there were any patterns or clustering 
among symptoms. Factors were extracted using maximum likelihood and rotated using the oblique method 
(direct oblimin). Any participants who had missing values were not included. Three factors were ident ified, with 
factor 1 having an eigenvalue of 3·30 accounting for 30·0% of the total variance, factor 2 an eigenvalue of 1·48 
and accounting for 13·4% of the variance, and factor 3 an eigenvalue of 1·02 and account for 9·3% (Figure i). 
The symptoms forming Factor 1 included urgency, daytime frequency and nighttime frequency, and therefore 
these items were combined into a summary GP-rated symptom severity score and used in analysis presented 
throughout this paper. 
Figure i: Scree plot of eigenvalues from a factor analysis of the GP-rated symptoms 
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Time to resolution of daytime frequency, nighttime frequency, and urgency 
Similarly, all 11 participant-rated symptoms were subjected to a factor analysis to determine if there were any 
patterns among symptoms in terms of time to recovery from them. Any participants who had missing values 
were not included, nor were patients whose symptoms had not recovered after 14 days. From examining both 
the scree plot (Figure ii) and the eigenvalues after extraction, two factors were identified showing two groups of 
symptoms that clustered together with regards to their time to recovery. Factor 1 displayed an eigenvalue of 
3·51 accounting for 31·9% of the variance, and Factor 2 displayed an eigenvalue of 1·18 and accounted for 
10·76% of the variance. The symptoms forming Factor 1 included urgency, daytime frequency and nighttime 
frequency, and this factor was used as part of the analysis of outcomes. 
Figure ii: Scree plot of eigenvalues from a factor analysis of the participant-rated symptoms 
 Page 27 of 39 
2.Time to full recovery analysis  
2.1 Univariable analyses 
Variable type Variable n 
Hazard 
Ratio 
95% Confidence Interval 
p-value 
Retain in 
multivariable 
analysis 
Lower Upper 
Case-mix Participants age at baseline 551 0·99 0·99 1·00 0·076 Yes 
Case-mix Clinician-rated symptom severity score 543 0·96 0·93 0·98 0·002 Yes 
Case-mix Number of days off work  
0 day 258     
No 
1 or more 35 0·91 0·59 1·40 0·657 
Case-mix Previous number of days with symptoms 
0 to 7 days 439    
0·026 
Yes 
8 to 14 days 62 0·67 0·47 0·96 
15 to 21 days 23 0·89 0·52 1·53 
22 days or more 22 0·48 0·26 0·91 
Case-mix Leukocytes 
Negative 80    
0·068 
No* 
+ 87 1·31 0·87 1·98 
++ 109 1·55 1·04 2·29 
+++ 169 1·58 1·11 2·27 
Case-mix Nitrites 
Negative 291     
No 
Positive 169 0·97 0·76 1·23 0·767 
Case-mix Protein 
Negative 245     
No 
Positive 186 0·97 0·75 1·24 0·775 
Case-mix Blood 
Negative 125     
No 
Positive 217 1·21 0·91 1·61 0·192 
Case-mix pH  
5 to 7 323     
No 
7·5 to 8·5 28 1·06 0·67 1·69 0·800 
Case-mix Cloudy urine 
No 260     
No* 
Yes 207 1·25 1·00 1·57 0·055 
Case-mix Offensive smell urine  
No 320     
No 
Yes 148 0·87 0·68 1·11 0·250 
Case-mix Temperature of participants at baseline 533 1·05 0·85 1·30 0·644 No 
Case-mix Diagnosed a urine infection in the past  
No 86     
Yes 
Yes 455 0·69 0·54 0·87 0·002 
Case-mix Number of treated urine infections in the past year 
0 221    
<0·001 
Yes 
1 88 0·62 0·45 0·85 
2 85 0·79 0·59 1·07 
3 or more 120 0·50 0·37 0·67 
Management Performed a dipstick test No 78     No 
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Yes 471 0·85 0·63 1·17 0·317 
Management 
Would have collected a urine sample under normal 
circumstances 
No 282     
No 
Yes 235 0·92 0·73 1·16 0·492 
Management Prescribed antibiotic 
No 56     
Yes 
Yes 494 1·66 1·10 2·50 0·015 
Management Organised follow-up 
No 371     
No 
Yes 169 0·84 0·65 1·09 0·196 
Exposure UTI 
No 307     
Yes 
Yes 194 1·24 0·98 1·57 0·074 
Exposure 
Wales 128 0·95 0·79 1·14 
0·919 Yes 
England 169 1·00 0·85 1·19 
Spain 150 1·06 0·89 1·26 
Netherlands 104 0·99 0·82 1.21 
*Due to the high number of missing responses regarding level of leukocytes and cloudy urine, these variables were not retained in the multivariable model. 
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2.2 Two-level Cox proportional hazards model of time to full recovery (participants nested within practices) 
Variable Hazard Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Age of participants at baseline 0·99 0·99 1·00 0·096 
Symptoms Severity Score 0·94 0·91 0·97 <0·001 
Previous number of days with symptoms 
0 to 7  Reference category 
8 to 14  0·76 0·51 1·13 
0·043 15 to 21  1·09 0·57 2·09 
22 or more  0·56 0·27 1·16 
Number of times a urine infection had been treated in the past year 
0 Reference category 
1 0·66 0·46 0·95 
0·002 2 0·79 0·54 1·14 
3 or more 0·53 0·37 0·75 
Prescribed antibiotic 
No Reference category 
Yes 1·69 1·05 2·72 0·006 
UTI 
No Reference category 
Yes 1·03 0·77 1·38 0·542 
Country 
Wales 0·99 0·80 1·22 0·900 
England 0·97 0·80 1·18 0·770 
Spain 0·98 0·80 1·19 0·810 
The Netherlands 1·07 0·84 1·37 0·588 
*Model based on 457 participants· Countries compared to the overall average 
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2.3 Two-level Cox proportional hazards model of time to full recovery with countries compared to England (participants nested within practices) 
Variable Hazard Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Age of participants at baseline 0·994 0·988 1·001 0·096 
Clinician-rated symptom severity score 0·948 0·920 0·976 <0·001 
Previous number of days with symptoms 
0 to 7  Reference category 
8 to 14  0·641 0·437 0·941 
0·043 15 to 21  0·996 0·548 1·810 
22 or more  0·519 0·263 1·027 
Number of times a urine infection had been 
treated in the past year 
0 Reference category 
1 0·692 0·496 0·966 
0·002 2 0·840 0·604 1·170 
3 or more 0·556 0·405 0·762 
Prescribed antibiotic 
No Reference category 
Yes 1·894 1·199 2·993 0·006 
UTI 
No Reference category 
Yes 
1·083 0·837 1·402 0·542 
Country 
England Reference category 
Wales 1·02 0·74 1·40 
0·959 Spain 1·00 0·74 1·37 
The Netherlands 1·10 0·76 1·60 
*Model based on 457 participants· Countries compared to The Netherlands  
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3.Time to resolution of moderately bad symptoms 
3.1 Univariable analyses 
Variable type Variable n Hazard Ratio 
95% Confidence Interval 
p-value 
Retain in multivariable 
analysis Lower Upper 
Case-mix Participants age at baseline 551 1·00 1·00 1·00 0·794 No 
Case-mix Clinician-rated symptom severity score 543 0·95 0·93 0·97 <0·001 Yes 
Case-mix Number of days off work 
0 day 258     
No 
1 or more 35 0·98 0·68 1·41 0·892 
Case-mix 
Previous number of days with 
symptoms 
0 to 7 days 439    
0·068 Yes 
8 to 14 days 62 0·80 0·61 1·07 
15 to 21 days 23 0·67 0·42 1·08 
22 days or more 222 0·65 0·40 1·05 
Case-mix Leukocytes 
Negative 80    
0·584 No 
+ 87 0·97 0·70 1·35 
++ 109 0·99 0·72 1·37 
+++ 169 1·14 0·85 1·51 
Case-mix Nitrites 
Negative 291     
No 
Positive 169 0·94 0·76 1·15 0·525 
Case-mix Protein 
Negative 245     
No 
Positive 186 1·02 0·82 1·25 0·883 
Case-mix Blood 
Negative 125     
No 
Positive 217 1·02 0·81 1·29 0·849 
Case-mix pH  
5·0 to 7 323     
No 
pH 7·5 to pH 8·5 28 0·98 0·66 1·46 0·928 
Case-mix Cloudy urine 
No 260     
No 
Yes 207 1·06 0·87 1·28 0·592 
Case-mix Offensive smell urine 
No 320     
No* 
Yes 148 0·79 0·64 0·97 0·023 
Case-mix Temperature of participants at baseline 533 1·06 0·89 1·27 0·521 No 
Case-mix 
Diagnosed a urine infection in the 
past 
No 86     
yes 
Yes 445 0·69 0·54 0·87 0·002 
Case-mix 
Number of urine infections 
treated in the past year 
0 221    
0·001 Yes 
1 88 0·76 0·58 0·99 
2 85 0·69 0·53 0·90 
3 or more 120 0·62 0·49 0·79 
Management Performed a dipstick test 
No 78     
No 
Yes 471 1·12 0·85 1·47 0·427 
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Management 
Would have collected a urine 
sample under normal 
circumstances 
No 282     
No 
Yes 235 1·05 0·86 1·28 0·623 
Management Prescribed antibiotic 
No 56     
No 
Yes 494 1·13 0·82 1·57 0·456 
Management Organised follow-up 
No 371     
No 
Yes 169 0·84 0·67 1·05 0·122 
Exposure UTI 
No 307     
Yes (exposure of interest)  
Yes 194 1·05 0·86 1·29 0·618 
Exposure 
Wales 128 0·98 0·84 1·15 
0·738 Yes (exposure of interest) 
England 169 1·01 0·88 1·16 
Spain 150 1·08 0·93 1·25 
Netherlands 104 0·93 0·79 1·11 
*Due to the high number of missing responses in offensive smelling urine, this variable was not retained in the multivariable model 
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3.2 Two-level Cox proportional hazards model of time to resolution of moderately bad symptoms with countries compared to the overall average (participants nested within practices) 
Variable Hazard Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Clinician-rated symptom severity score 0·955 0·932 0·979 <0·001 
Previous number of days with symptoms 
0 to 7 days Reference category 
8 to 14 days 0·781 0·576 1·059 
0·0503 15 to 21 days 0·687 0·411 1·149 
22 days or more 0·573 0·343 0·957 
Number of times a urine infection had been treated in past year 
0 Reference category 
1 0·826 0·628 1·086 
0·016 2 0·724 0·543 0·966 
3 or more 0·680 0·525 0·883 
UTI 
No Reference category 
Yes 0·987 0·798 1·221 0·906 
Country 
Wales 1·101 0·922 1·314 
0·640 
England 0·971 0·824 1·144 
Spain 1·027 0·867 1·217 
Netherlands 0·911 0·753 1·104 
*Model based on 457 participants· Countries compared to the overall average 
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4. Time to resolution of daytime frequency, nighttime frequency, and urgency 
4.1. Univariable analyses 
Variable type Variable n 
Hazard 
Ratio 
95% Confidence 
Interval p-value 
Retain in 
multivariable 
analysis Lower Upper 
Case-mix Participants age at baseline 510 0·991 0·986 0·997 0·003 Yes 
Case-mix Clinician-rated symptom severity score 532 0·940 0·917 0·964 <0·001 Yes 
Case-mix Days off work 
0 days 256     
No 
1 or more days 35 0·911 0·601 1·379 0·658 
Case-mix Previous number of days with symptoms 
0 to 7 days 430    
0·091 Yes 
8 to 14 days 61 0·740 0·530 1·032 
15 to 21 days 22 0·818 0·487 1·374 
22 or more 22 0·589 0·336 1·032 
Case-mix Leukocytes 
Negative 79    
0·087 No* 
+ 86 1·134 0·772 1·664 
++ 105 1·450 1·007 2·087 
+++ 169 1·436 1·031 1·999 
Case-mix Nitrites 
Negative 287     
No 
Positive 165 0·981 0·780 1·234 0·872 
Case-mix Protein 
Negative 241     
No 
Positive 182 0·923 0·728 1·170 0·509 
Case-mix pH 
5·0 to 7·0 317     
No 
7·5 to 8·5 28 1·174 0·754 1·827 0·478 
Case-mix Blood dipstick result  
Negative 120     
No 
Positive 216 1·126 0·859 1·477 0·391 
Case-mix Cloudy urine 
No 256     
No* 
Yes 203 1·208 0·971 1·503 0·090 
Case-mix Offensive smell urine 
No 314     
No 
Yes 146 0·850 0·674 1·071 0·168 
Case-mix Temperature of participants at baseline 524 1·055 0·858 1·298 0·610 No 
Case-mix Diagnosed UTI in the last year 
No 84     
Yes 
Yes 436 0·794 0·608 1·038 0·092 
Case-mix Number of UTI diagnosed in the last year 
0 219    
0·003 Yes 
1 86 0·846 0·637 1·124 
2 82 0·722 0·536 0·973 
3 or more 116 0·542 0·409 0·717 
Management Performed a dipstick test No 75     No 
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Yes 463 0·826 0·612 1·113 0·209 
Management 
Would have collected a urine sample 
under normal circumstances 
No 274     
No 
Yes 233 0·900 0·722 1·121 0·348 
Management Prescribed antibiotic 
No 54     
No 
Yes 485 1·249 0·861 1·812 0·241 
Management Organised follow-up 
No 364     
No 
Yes 165 0·916 0·718 1·169 0·482 
Exposure UTI 
No 302     
No 
Yes 189 1·18 0·94 1·48 0·154 
Exposure 
Wales 126 0·91 0·76 1·09 
0·742 Yes 
England 168 1·03 0·88 1·21 
Spain 145 1·07 0·90 1·26 
Netherlands 101 1·00 0·83 1·20 
*Due to the high number of missing responses regarding level of leukocytes and cloudy urine, these variables were not retained in the multivariable model. 
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4.2. Two-level Cox proportional hazards model of time to resolution of daytime frequency, nighttime frequency, and urgency with countries compared to the overall average (participants 
nested within practices) 
Variable Hazard Ratio 
95% Confidence Interval 
p-value 
Lower Upper 
Participants age at baseline 0·99 0·99 1·00 0·026 
Symptoms severity score 0·94 0·91 0·97 <0·001 
Previous number of days with symptoms 
0 to 7  Reference category 
8 to 14  0·77 0·54 1·09 
0·248 15 to 21  0·91 0·52 1·60 
22 or more 0·63 0·35 1·14 
Number of time a urine infection had been 
treated in the past year 
0 Reference category 
1 0·92 0·68 1·24 
0·018 2 0·78 0·56 1·08 
3 or more 0·62 0·46 0·84 
UTI 
No Reference category 
Yes 1·13 0·89 1·44 0·324 
Country 
Wales 1·00 0·82 1·24 
0·788 
England 1·06 0·89 1·28 
Spain 1·04 0·86 1·25 
Netherlands 0·90 0·73 1·12 
*Model based on 447 participants· Countries compared to the overall average·  
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5· Relationship between time to recovery, antibiotic prescribing, and UTI 
 
Time to full recovery 
UTI 
Yes No Total 
Prescribed antibiotic  
Yes 178, 8 (5, 14) 270, 10 (6, 14) 494, 9 (5, 14)  
No 16, 12 (8, 14) 36, 14 (7, 14) 56, 14 (7, 14) 
Total 194, 9 (6, 14)  307, 10 (6, 14)  
 
 
Time to resolution of moderately bad symptoms 
UTI 
Yes No Total 
Prescribed antibiotic 
Yes 178, 3 (3, 6) 270, 4 (2, 6) 494, 4 (2, 6) 
No 16, 3 (2·5, 5·5) 36, 4 (2, 8·5) 56, 3·5 (2, 8) 
Total 194, 3 (3, 6) 307, 4 (2, 6)  
 
 
Time to resolution of daytime frequency, night time frequency, and urgency 
UTI 
Yes No Total 
Prescribed antibiotic 
Yes 173, 6 (4, 13) 267, 8 (5, 14) 485, 8.5 (5, 14) 
No 16, 9 (5, 14) 34, 9 (4, 14) 54, 7 (4, 14) 
Total 189, 8 (5, 14) 302, 7 (5, 14)   
*n, Median (IQR)
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6. Full search strategy for systematic review 
OVID Medline Search Strategy (1946 to January week 3 2014); 
1. exp Primary Health Care/ 
2. exp General Practice/ 
3. exp Family Practice/ 
4. exp Group Practice/ 
5. primary care.mp. 
6. general practice.mp. 
7. group practice.mp. 
8. family practice.mp. 
9. exp Physicians, Family/ 
10. exp Physician-Patient Relations/ 
11. primary healthcare.mp. 
12. family physician*.mp. 
13. primary health care.mp. 
14. general practi*.mp. 
15. family practi*.mp. 
16. family doctor*.mp. 
17. or/1-16 
18. exp Urinary Tract Infections/ 
19. exp Bacteriuria/ 
20. exp Cystitis/ 
21. exp Cystitis, Interstitial/ 
22. exp Escherichia coli Infections/ 
23. exp Pyelonephritis/ 
24. bacteriuria.mp. 
25. (urinary adj2 infection*).tw. 
26. (Urinary Tract Infection* or UTI).mp. 
27. cystitis.tw. 
28. bladder infection*.mp. 
29. or/18-28 
30. (Albania or Andorra or Armenia or Austria or Azerbaijan or Belarus or Belgium or Bosnia & Herzegovina 
or Bulgaria or Croatia or Cyprus or Czech Republic or Denmark or Estonia or Finland or France or Georgia or 
Germany or Greece or Hungary or Iceland or Ireland or Italy or Kosovo or Latvia or Liechtenstein or Lithuania 
or Luxembourg or Macedonia or Malta or Moldova or Monaco or Montenegro or The Netherlands or Norway or 
Poland or Portugal or Romania or Russia or San Marino or Serbia or Slovakia or Slovenia or Spain or Sweden 
or Switzerland or Turkey or Ukraine or United Kingdom or Vatican City or Holland or Great Britain or  Britain 
or England or Scotland or Wales or UK or welsh or scottish or irish).tw. 
31. 17 and 29 and 30 
32. "Pregnancy"/ 
33. pregnan*.mp. 
34. exp Catheters/ 
35. or/32-34 
36. 31 not 35 
37. limit 36 to english language 
